BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20719225)

  • 1. US physicians' intentions regarding impact of human papillomavirus vaccine on cervical cancer screening.
    Wong C; Berkowitz Z; Saraiya M; Wideroff L; Benard VB
    Sex Health; 2010 Sep; 7(3):338-45. PubMed ID: 20719225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Models of cervical screening in the era of human papillomavirus vaccination.
    Canfell K
    Sex Health; 2010 Sep; 7(3):359-67. PubMed ID: 20719228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program.
    Brotherton JM; Leask J; Jackson C; McCaffery K; Trevena LJ
    Sex Health; 2010 Sep; 7(3):291-8. PubMed ID: 20719217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
    Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
    Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.
    Pitts MK; Heywood W; Ryall R; Smith AM; Shelley JM; Richters J; Simpson JM
    Sex Health; 2010 Sep; 7(3):299-303. PubMed ID: 20719218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus vaccines: an update for gynecologists.
    Ault KA
    Clin Obstet Gynecol; 2008 Sep; 51(3):527-32. PubMed ID: 18677145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination against human papillomaviridae. Expert correspondence no. 18 of 29 December 2006].
    Kommission Qualitätssicherung der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe
    Gynakol Geburtshilfliche Rundsch; 2007; 47(2):101-2. PubMed ID: 17440273
    [No Abstract]   [Full Text] [Related]  

  • 8. Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience.
    Heffernan ME; Garland SM; Kane MA
    Sex Health; 2010 Sep; 7(3):383-90. PubMed ID: 20719231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Survey among female university students on HPV infection epidemiology and prevention].
    Meleleo C; Sorbara D; Serino L; Di Rita R; Laudati F; Papa R; Renzi S; Senatore S; Cianti D; Zaratti L; Franco E
    Ig Sanita Pubbl; 2010; 66(4):563-8. PubMed ID: 21132046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine.
    Brotherton JM; Fairley CK; Garland SM; Gertig D; Saville M
    Sex Health; 2010 Sep; 7(3):397-8. PubMed ID: 21058499
    [No Abstract]   [Full Text] [Related]  

  • 11. Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective.
    Regan DG; Philp DJ; Waters EK
    Sex Health; 2010 Sep; 7(3):368-75. PubMed ID: 20719229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus vaccine acceptability among young adult men.
    Gerend MA; Barley J
    Sex Transm Dis; 2009 Jan; 36(1):58-62. PubMed ID: 18830138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rates of free human papillomavirus vaccine uptake among young women.
    Moore GR; Crosby RA; Young A; Charnigo R
    Sex Health; 2010 Sep; 7(3):287-90. PubMed ID: 20719216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What can surveillance of genital warts tell us?
    Fairley CK; Donovan B
    Sex Health; 2010 Sep; 7(3):325-7. PubMed ID: 20719222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccines against human papillomavirus (HPV); between registration and implementation].
    van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
    Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from the failure of human papillomavirus vaccine state requirements.
    Schwartz JL; Caplan AL; Faden RR; Sugarman J
    Clin Pharmacol Ther; 2007 Dec; 82(6):760-3. PubMed ID: 17971822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccine acceptability among a national sample of adult women in the USA.
    Stupiansky NW; Rosenthal SL; Wiehe SE; Zimet GD
    Sex Health; 2010 Sep; 7(3):304-9. PubMed ID: 20719219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brief history of economic evaluation for human papillomavirus vaccination policy.
    Beutels P; Jit M
    Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'It's a logistical nightmare!' Recommendations for optimising human papillomavirus school-based vaccination experience.
    Robbins SC; Bernard D; McCaffery K; Skinner SR
    Sex Health; 2010 Sep; 7(3):271-8. PubMed ID: 20719214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.